eligibility_summary
Adults 18-70 with CD1a+ T-ALL or T-LBL, consented, lacking effective options or choosing salvage anti-CD1a CAR-T. Eligible if refractory/relapsed (incl post-HSCT/cell therapy) or high risk, measurable disease, organ function: ALT/AST <3xULN, bilirubin <=34.2 umol/L, creatinine <220 umol/L, SpO2 >=95%, LVEF >=40%, >=4-wk washout, ECOG <=2, >=3-mo survival, venous access. Exclude pregnancy, poor contraception, active infection (HBV/HCV/HIV), autoimmune/immunodeficiency, biologic allergy, recent trials/steroids, mental illness, substance abuse, or other unsuitability.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Autologous anti‑CD1a CAR‑T cells (biologic, gene‑modified cell therapy) infused after fludarabine/cyclophosphamide lymphodepletion. Mechanism: Patient T cells are engineered with a chimeric antigen receptor that recognizes CD1a, CAR signaling (CD3ζ with costimulation) activates T‑cell cytotoxic pathways (perforin/granzyme) and proliferation to kill CD1a‑expressing tumor cells. Targets: CD1a on cortical‑type T‑ALL/T‑LBL blasts, largely absent on CD34+ progenitors and mature T cells, with low expression on Langerhans/dendritic cells, some B cells, and GI epithelium. Aim: assess safety/efficacy in r/r CD1a+ T‑ALL/LBL (single‑arm Phase 2, China).